EMA Recommends Extension of Indications for Serplulimab By Ogkologos - April 22, 2026 135 0 Facebook Twitter Google+ Pinterest WhatsApp New indications concern the treatment of patients with oesophageal squamous cell carcinoma and non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Approves Ivosidenib for Advanced or Metastatic Cholangiocarcinoma August 30, 2021 Workout Wednesday – Leg Stretches Part 1 July 8, 2020 Νέα για τον καρκίνο του προστάτη June 9, 2019 Triple Blockade Demonstrates High Response Rates in Metastatic Melanoma October 14, 2020 Load more HOT NEWS FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma Fragment Analysis Is a More Reliable MET Exon 14 Screening Strategy... She Faced Breast Cancer At 16 With Little Help From Doctors.... Selpercatinib Shows Durable Efficacy in RET Fusion–positive NSCLC
